Targeted oral fixed-dose combination of amphotericin B and miltefosine for visceral leishmaniasis

Tools

Fernández-García, Raquel and Walsh, David and O'Connell, Peter and Domingues Passero, Luiz Felipe and de Jesus, Jéssica A. and Laurenti, Marcia Dalastra and Dea-Ayuela, María Auxiliadora and Ballesteros, M. Paloma and Lalatsa, Aikaterini and Bolás-Fernández, Francisco and Healy, Anne Marie and Serrano, Dolores R. (2025) Targeted oral fixed-dose combination of amphotericin B and miltefosine for visceral leishmaniasis. Molecular Pharmaceutics. ISSN 1543-8384 (In Press)

[thumbnail of Fernandez-Garcia-etal-MP-2025-Targeted-oral-fixed-dose-combination-of-amphotericin-B-and-miltefosine] Text. Filename: Fernandez-Garcia-etal-MP-2025-Targeted-oral-fixed-dose-combination-of-amphotericin-B-and-miltefosine.pdf
Accepted Author Manuscript
Restricted to Repository staff only until 1 January 2099.
Download (2MB) | Request a copy

Abstract

The incidence of visceral leishmaniasis (VL) remains a significant health threat in endemic countries. Fixed-dose combination (FDC) of amphotericin B (AmB) and miltefosine (MLT) is a promising strategy for treating VL, but the parenteral administration of AmB leads to severe side effects, limiting its use in clinical practice. Here, we developed novel FDC granules combining AmB in the core with a MLT coating using wet granulation followed by fluidized bed technology. The granules maintained the crystalline structure of AmB throughout manufacturing, achieving an AmB loading of ~20%. The MLT coating layer effectively sustained AmB release from 3 to 24 hours following Korsmeyer-Peppas kinetics. The formulation demonstrated remarkable stability, maintaining >90% drug content for over a year at both 4 °C and room temperature under desiccated conditions. In vivo efficacy studies in L. infantum-infected hamsters showed 65-80% reduction in parasite burden in spleen and liver respectively, suggesting potential as an oral alternative to current VL treatments. Uncoated and coated granules demonstrated comparable performance in key aspects, including in vivo efficacy and long-term stability.

ORCID iDs

Fernández-García, Raquel, Walsh, David, O'Connell, Peter, Domingues Passero, Luiz Felipe, de Jesus, Jéssica A., Laurenti, Marcia Dalastra, Dea-Ayuela, María Auxiliadora, Ballesteros, M. Paloma, Lalatsa, Aikaterini ORCID logoORCID: https://orcid.org/0000-0003-4791-7468, Bolás-Fernández, Francisco, Healy, Anne Marie and Serrano, Dolores R.;
CORE (COnnecting REpositories)